This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Dermatologic Disorders, Other  • Drug Therapy  • Alert me on articles by topic

Alexander Kreuter, MD; Thilo Gambichler, MD; Frank Breuckmann, MD; Sebastian Rotterdam, MD; Marcus Freitag, MD; Markus Stuecker, MD; Klaus Hoffmann, MD; Peter Altmeyer, MD

Arch Dermatol. 2005;141:847-852.

Objective  To evaluate the efficacy of pulsed high-dose corticosteroids combined with orally administered low-dose methotrexate therapy in patients with severe localized scleroderma (LS).

Design  A prospective, nonrandomized, open pilot study.

Setting  Dermatology department at a university hospital in Bochum, Germany.

Patients  Fifteen patients with histologically confirmed severe LS.

Interventions  Oral methotrexate (15 mg/wk) combined with pulsed intravenous methylprednisolone (1000 mg for 3 days monthly) for at least 6 months.

Main Outcome Measures  Treatment outcome was evaluated by means of a clinical score, 20-MHz ultrasonography, and histopathologic analysis. Safety assessment included the monitoring of adverse effects and clinical laboratory parameters.

Results  One patient discontinued therapy. In most of the remaining 14 patients, significant elimination of all signs of active disease (inflammation) and remarkable softening of formerly affected sclerotic skin that resulted in a decrease of the mean ± SD clinical score from 10.9 ± 5.3 at the beginning to 5.5 ± 2.5 at the end of therapy was observed (P<.001). Clinical improvement was confirmed by histologic and ultrasonographic assessments. No serious adverse effects were noted.

Conclusions  These data suggest that pulsed high-dose corticosteroids combined with orally administered low-dose methotrexate therapy is beneficial and safe in the treatment of patients with LS. This treatment regimen should especially be considered for severe forms of LS in which conventional treatments have failed.

Author Affiliations: Department of Dermatology and Allergology, Ruhr-University Bochum, Bochum, Germany.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

UV-A1 Phototherapy for Sclerotic Skin Diseases: Implications for Optimizing Patient Selection and Management
Kreuter and Gambichler
Arch Dermatol 2008;144:912-916.
FULL TEXT  

Ultrasonography is a sensitive tool for monitoring localized scleroderma
Li et al.
Rheumatology (Oxford) 2007;46:1316-1319.
ABSTRACT | FULL TEXT  

A new computerized method for the assessment of skin lesions in localized scleroderma
Zulian et al.
Rheumatology (Oxford) 2007;46:856-860.
ABSTRACT | FULL TEXT  

Methotrexate with Pulsed Methylprednisolone Is Effective for Localized Scleroderma
Journal Watch Dermatology 2005;2005:6-6.
FULL TEXT